Abstracts tagged "pregnancy"

Abstract Number: 0431 • ACR Convergence 2024
Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors
Abraham Yair Lujano-Negrete¹, Lorena Perez-Barbosa², Conrado Garcia³, CASSANDRA SKINNER TAYLOR⁴, Jose Hernandez Linas³, Adriana Lobato-Belmonte³, Yesenia Ambriz Murillo⁵, Alfonso Gastelum-Strozzi⁶, Amaranta Manrique de Lara⁷, Ana Rodriguez-Flores⁸, Jesus Cardenas-de la Garza⁹, Marco Maradiaga-Cecena¹⁰, Galilea Rodriguez Orozco¹¹, Anahí Carrazco Chapa¹¹, Dionicio Galarza-Delgado¹² and Ingris del Pilar Pelaez Ballestas³, and Grupo de estudio de salud reproductiva en enfermedades reumáticas autoinmunes en Mexico, ¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Internal Medicine, Monterrey, Mexico, Monterrey, Mexico, ²Hospital Universitario, UANL, Monterrey, Mexico, ³Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico, Mexico, ⁴HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁵Hospital Regional de Morelia, Rheumatology, Morelia, Mexico, Morelia, Mexico, ⁶Instituto de Ciencias Aplicadas y Tecnología, UNAM, Mexico City, Mexico, Monterrey, Mexico, ⁷Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico City, Mexico, ⁸Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ¹⁰Hospital General de Culiacan, Rheumatology, Culiacan, Mexico, Culiacan, Sinaloa, Mexico, ¹¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ¹²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) affect women during their childbearing years, often leading to pregnancy complications. Effective management of this population requires family planning and…
Abstract Number: 0451 • ACR Convergence 2024
Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome
Juan J. Fierro¹, Mirthe Schoots¹, Silvia Liefers¹, Berber Doornbos-van der Meer², Gilles Diercks¹, Hendrika Bootsma³, Jelmer R. Prins¹, Johanna Westra¹ and Karina de Leeuw⁴, ¹University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, ²University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Groningen, Netherlands
Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…
Abstract Number: 1647 • ACR Convergence 2024
Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
Cornelia H. Quaack¹, Esther Röder¹, Hetty M. Wintjes¹, Anneke J. van Steensel-Boon¹, Annemarie G.M.G.J. Mulders², Laura C.J. Kranenburg-van Koppen¹ and radboud J.e.m. Dolhain¹, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…
Abstract Number: 0432 • ACR Convergence 2024
Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study
Marion couderc¹, celine lambert², sabrina hamroun³, denis gallot⁴, Nathalie Costedoat-chalumeau⁵, Laure Gossec⁶, Gaëlle Guettrot-Imbert⁷, Veronique LE GUERN⁷, Christophe Richez⁸, MArtin Soubrier⁹ and Anna Molto¹⁰, ¹CHU de Clermont-Ferrand, Clermont-Ferrand, ²chu clermont ferrand, clermont ferrand, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, ⁵University Paris Cité, Paris, France, ⁶Sorbonne Université, Paris, France, ⁷Cochin Hospital, Paris, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁰Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
Abstract Number: 0453 • ACR Convergence 2024
Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family
Andrea Pluma¹, Linda Rüegg², Sabrina Hamroun³, Axel Finckh⁴, Yvette Meissner⁵ and Frauke Foerger⁶, ¹Vall d'Hebron University Hospital, Barcelona, Spain, ²Inselspital, Bern University Hospital, Bern, Switzerland, ³Cochin University Hospital, Paris, Ile-de-France, France, ⁴Geneva University Hospital, Geneva, Switzerland, ⁵Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁶University hospital Bern /Inselspital Bern, Bern, Switzerland
Background/Purpose: Counselling patients with rheumatic and musculoskeletal diseases (RMD) in the phase of reproduction, pregnancy and breastfeeding is a challenging task. The potential risk of…
Abstract Number: 1702 • ACR Convergence 2024
Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Naomi I. Maria², Zhengzi Yi³, Chirag Raparia⁴, Gayathri Konanur Gopikrishna¹, Weijia Zhang³ and Anne Davidson², ¹Feinstein Institutes for Medical Research, Manhasset, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Mt. Sinai School of Medicine, New York, NY, ⁴Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY
Background/Purpose: Antiphospholipid antibodies (aPL) confer a high risk for adverse pregnancy outcomes, especially in women with SLE. aPLs can induce pro-inflammatory signaling via TLR8 receptors,…
Abstract Number: 0434 • ACR Convergence 2024
Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Vienna Cheng¹, Neda Amiri², Vicki Cheng¹, Ursula Ellis³, Jacquelyn J. Cragg¹, Mark Harrison¹ and Mary A. De Vera¹, ¹University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, ³University of British Columbia, Woodward Library, Vancouver, BC, Canada
Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…
Abstract Number: 0455 • ACR Convergence 2024
Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project
Ikwinder Preet Kaur¹, Gurjit Kaeley², Cristine Arcilla³, Ngun Par⁴ and Thway Myant⁵, ¹University of Florida College of Medicine, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL, ³University of Florida Jacksonville, Jacksonville, FL, ⁴University of Florida Jacksonville Physicians Inc, Jacksonville, ⁵UF Jacksonville, Mia, FL
Background/Purpose: RMD patients are at increased risk of adverse pregnancy outcomes either from the active disease itself or the use of immunosuppressants incompatible with pregnancy.…
Abstract Number: 1770 • ACR Convergence 2024
Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Nalani Sachan¹, Christina Firl², Philip Carlucci³, Nicola Fraser², Robert Clancy⁴ and Jill Buyon⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
Abstract Number: 0436 • ACR Convergence 2024
Family Planning in Rheumatology: A Single Center Quality Improvement Project
Sara Heard, Elena Cravens, Jeanne Gosselin and Juvena Hitt, University of Vermont Medical Center, Burlington, VT
Background/Purpose: Pregnancy in patients with rheumatologic disease can lead to serious maternal and fetal complications. Multinational surveys have shown that medical providers often fail to…
Abstract Number: 0576 • ACR Convergence 2024
Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up
Madeleine FRANC¹, Anne Tournadre² and Anna Molto³, ¹Groupe Hospitalier Cochin, APHP, Paris, France, ²Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ³Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Only scarce data is available regarding pregnancy outcomes in early axSpA. The objective of this study was to determine (a) the factors associated with…
Abstract Number: 1869 • ACR Convergence 2024
Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases
Shunya Kaneshita¹, Christina Chambers², Diana Johnson¹, Arthur Kavanaugh¹, Richard Garfein¹ and Gretchen Bandoli¹, ¹University of California San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant women are particularly at risk of severe Coronavirus disease 2019 (COVID-19) infection, which is why the Centers for Disease Control and Prevention (CDC)…
Abstract Number: 0437 • ACR Convergence 2024
Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis
Deirdre Quinn¹, Florentina Sileanu¹, Gregory Procario¹, Shannon Mitchell¹ and Mehret Birru Talabi², ¹VA Pittsburgh Healthcare System, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…
Abstract Number: 0577 • ACR Convergence 2024
AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
Madeleine FRANC¹, Jean Guibourdenche², Anne Tournadre³ and Anna Molto⁴, ¹Groupe Hospitalier Cochin, APHP, Paris, France, ²Groupe Hospitalier Cochin, APHP, Paris, ³Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Data on fertility in women with spondyloarthritis (SpA) is sparse but seems to be impaired compared to the general population. Divergent results have been…
Abstract Number: 1893 • ACR Convergence 2024
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
Amadeia Rector¹, Emily Liu², Miranda Cantu³, Eliza Chakravarty⁴, Maurice Druzin⁵, Gary Shaw⁶, Michael Weisman⁷, Monique Hedderson² and Julia Simard⁸, ¹Stanford University, San Francisco, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Patient partner, Portage, MI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Stanford University School of Medicine, Stanford, ⁷Stanford University, Los Angeles, CA, ⁸Stanford School of Medicine, Stanford, CA
Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].